Brief: Allarity Therapeutics Cash & Cash Receivable Balance Of $20.9 Million As Of Dec 31, Expected To Fund Operations, Including Clinical Activities Into 2027
31/03/2025 23:43
Allarity Therapeutics Inc ALLR.O: ALLARITY THERAPEUTICS: CASH & CASH RECEIVABLE BALANCE OF $20.9 MILLION AS OF DEC 31, EXPECTED TO FUND OPERATIONS, INCLUDING CLINICAL ACTIVITIES INTO 2027 ALLARITY THERAPEUTICS: ENROLLMENT IN NEW PHASE 2 SCLC TRIAL TO BEGIN IN Q2-Q3 2025, FULLY FUNDED BY U.S. VETERANS ADMINISTRATION Source text: ID:nGNX6nrXZ8 Further company coverage: ALLR.O
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic